ONCASPAR logo; ONCASPAR pegaspargase injection.

ONCASPAR® as a component of an ALL treatment regimen

Photograph of a man in a hospital bed being given a green teddy bear by a young child.

Indication

ONCASPAR® is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with ALL.1

Learn more about Servier Canada’s treatment options in ALL

Consult the ONCASPAR® Product Monograph

Over 25 years of market experience worldwide*

ONCASPAR® is the first PEGylated asparaginase in Canada

aBFM: augmented Berlin-Frankfurt-Münster; ALL: acute lymphoblastic leukemia; BSA: body surface area; CNS: central nervous system; CSF: cerebrospinal fluid; DFCI: Dana-Farber Cancer Institute; ELISA: enzyme-linked immunosorbent assay; IM: intramuscular; IV: intravenous; PD: pharmacodynamics; PK: pharmacokinetics; NCCN: National Comprehensive Cancer Network®; TDM: therapeutic drug monitoring.

* Clinical significance has not been established.

† Comparative clinical significance has not been established.

‡ Fictitious cases. May not be representative of all patients.

§ Native E. coli L-asparaginase is not available in Canada.

References: 

  1. ONCASPAR® Product Monograph. Servier Canada. August 20, 2024.
  2. ONCASPAR_CPID Redacted.
  3. ASPARLAS® Product Monograph. Servier Canada. March 8, 2024.
  4. RYLAZE™ Product Monograph. Jazz Pharmaceuticals Canada Inc.
  5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.2.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed November 8, 2024.
  6. Vrooman LM et al. Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: Results of DFCI 11-001. J Clin Oncol. 2021;39(31):3496–3505.

Stay Connected with Servier Canada

Stay up to date on disease information, treatment options, our products, and patient support programs.

Sign Up